- Home
- INZY
INZY
Inozyme Pharma Inc.
as 04-18-2025 1:38pm EST
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 64.9M | IPO Year: | 2020 |
| Target Price: | $17.22 | AVG Volume (30 days): | 453.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.72 - $6.24 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Inozyme Pharma Inc. (INZY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Treco Douglas A | INZY | CEO & Chairman | Apr 1 '25 | Sell | $0.89 | 8,819 | $7,848.91 | 41,046 |
Latest Inozyme Pharma Inc. News
INZY Breaking Stock News: Dive into INZY Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
GlobeNewswire
19 days ago
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
MT Newswires
a month ago
Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating
GlobeNewswire
a month ago
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
GlobeNewswire
2 months ago
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire
2 months ago
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
GlobeNewswire
3 months ago
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
MT Newswires
4 months ago
Raymond James Initiates Inozyme Pharma at Outperform With $26 Price Target
Compare INZY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INZY Inozyme Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.